Molecular mechanisms of resistance and new therapeutic approaches in the treatment of colorectal cancer - a review of the literature
DOI:
https://doi.org/10.12775/JEHS.2024.66.55620Keywords
colorectal cancer, chemotherapy, therapeutic targets, kras, braf, mmr deficencyAbstract
CRC occupies one of the leading positions among gastrointestinal malignancies and is a significant problem in Europe since it is the third most frequently diagnosed cancer. Recent developments in diagnostic techniques have led to higher chances of early diagnosis and survival; nevertheless, CRC is highly likely to relapse in the survivorably younger individuals. The importance of the current chemotherapy treatment and potential key therapeutic targets are identified in this review so that the molecular alterations causing drug resistance in CRC can be studied.Current literature formed the basis of this review by reviewing the molecular processes that underlie CRC, with emphasis on the mutational alterations in genes such as SENP1, KRAS, APC, TP53, and BRAF that play critical roles in CRC and resistance to treatment. Chemotherapy for CRC, targeting therapies, and immuno therapies have been discussed particularly with reference to their effectiveness for treatment and overcoming resistance.Genomic alterations in some important genes are involved in the onset of CRC and also determined the response to therapies. The KRAS mutations are associated with the resistance to EGFR inhibitors; however, BRAF mutations require BRAF/MEK inhibitors. Lack of MMR system SSR as a trigger for MSI-H status suggests a better response to immunotherapies. In addition, new molecules including SENP1, which involved the DNA repair pathway, and combination using CDK4/6 inhibitors are currently under development to overcome resistance and enhance the patients’ benefits.Colorectal cancer is still a problem, primarily because of its genetic character and high rates of recurrence. Even though chemotherapy and targeted therapies offer helpful results, the problem of resistance stands in the way. Subsequent studies should aim at symptomatic treatment outcomes and combine different drugs in order to enhance long-term treatment outcomes.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A cancer journal for clinicians. 2024 Apr 4;74(3):229–63.
Meghana Kesireddy, Tenner L. Colon Cancer Survivorship in Patients Who Have Received Adjuvant Chemotherapy. Clinical Colorectal Cancer. 2023 Dec 1;22(4):361–74.
Chang KJ, Kim DH, Lalani TK, Viktoriya Paroder, Pickhardt PJ, Shaish H, et al. Radiologic T staging of colon cancer: renewed interest for clinical practice. Abdominal Radiology. 2023 Jun 5;48(9):2874–87.
Seok In Seo, Lim SB, Yong Sik Yoon, Chan Wook Kim, Chang Sik Yu, Tae Won Kim, et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. Journal of Surgical Oncology. 2013 Jun 10;108(1):9–13.
Tonini V, Zanni M. Why is early detection of colon cancer still not possible in 2023? World Journal of Gastroenterology [Internet]. 2024 Jan 21 [cited 2024 Mar 24];30(3):211–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10835528/
Audisio A, Fazio R, Daprà V, Assaf I, Hendlisz A, Sclafani F. Neoadjuvant chemotherapy for early-stage colon cancer. Cancer Treatment Reviews [Internet]. 2024 Feb 1 [cited 2024 Jan 11];123:102676. Available from: https://www.sciencedirect.com/science/article/pii/S030573722300169X?casa_token=no-71BtBx8sAAAAA:mGV1I--GjBbWwSCG712YMnpPrX7D5ezayblZUgs2VVeIfPaEmwZJBvR-H4TJRzbykt1xHJ4wp4Q
Hsu WH, LaBella KA, Lin Y, Xu P, Lee R, Hsieh CE, et al. Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression. Cancer discovery. 2023 Sep 27;13(12):2652–73.
Wei M, Huang X, Liao L, Tian Y, Zheng X. SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer. Cancer research. 2023 Jun 23;83(17):2908–23.
Recio-Boiles A, Waheed A, Cagir B. Colon cancer [Internet]. Nih.gov. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/
Yasutoshi Kuboki, Fakih M, Strickler J, Yaeger R, Toshiki Masuishi, Kim EJ, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature Medicine [Internet]. 2024 Jan 1 [cited 2024 Oct 13];30(1):265–70. Available from: https://pubmed.ncbi.nlm.nih.gov/38177853/
Yang K, Zhu L, Liu C, Zhou D, Zhu Z, Xu N, et al. Current status and prospect of the DNA double-strand break repair pathway in colorectal cancer development and treatment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease [Internet]. 2024 Jul 25 [cited 2024 Oct 13];1870(7):167438–8. Available from: https://www.sciencedirect.com/science/article/pii/S0925443924004319
J. Taieb, Sinicrope FA, Pederson L, S. Lonardi, Alberts SR, George TJ, et al. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Annals of Oncology [Internet]. 2023 Aug 23 [cited 2024 Oct 13];34(11):1025–34. Available from: https://www.sciencedirect.com/science/article/pii/S0923753423008049?via%3Dihub
Hosea R, Duan W, Meliala ITS, Li W, Wei M, Hillary S, et al. YY2/BUB3 Axis promotes SAC Hyperactivation and Inhibits Colorectal Cancer Progression via Regulating Chromosomal Instability. Advanced Science [Internet]. 2024 Apr 29;11(26):2308690. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234461/
Wagner SJ, Reisenbüchler D, West NP, Jan Moritz Niehues, Zhu J, Foersch S, et al. Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study. Cancer Cell. 2023 Sep 1;41(9):1650-1661.e4.
Ros J, Baraibar I, Saoudi N, Rodriguez M, Salvà F, Tabernero J, et al. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers. Cancers [Internet]. 2023 Jan 1;15(17):4245. Available from: https://www.mdpi.com/2072-6694/15/17/4245
Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. 2022 May;23(5):659–70.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. New England Journal of Medicine. 2020 Dec 3;383(23):2207–18.
Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, et al. Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells. Cancer Discovery [Internet]. 2023 Oct 25; Available from: https://pubmed.ncbi.nlm.nih.gov/37877779/
Li W, Li L, Yang H, Shi C, Lei Z, Guo L, et al. Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant. Frontiers in Bioscience-Landmark [Internet]. 2024 Jul 25 [cited 2024 Oct 13];29(7):272. Available from: https://pubmed.ncbi.nlm.nih.gov/39082342/
Johnson D, Cheng Ean Chee, Wong W, Rachel C.T. Lam, Huat B, Brigette B.Y. Ma. Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions. Cancer Treatment Reviews [Internet]. 2024 Feb 25 [cited 2024 Oct 13];125:102700–0. Available from: https://pubmed.ncbi.nlm.nih.gov/38422896/
Lim SH, Lee SY, Hong JY, Lee J, Kim ST. CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells. Translational Cancer Research [Internet]. 2024 Jul [cited 2024 Oct 13];13(7):3695–703. Available from: https://pubmed.ncbi.nlm.nih.gov/39145064/
Lin KH, Istl AC, Quan D, Skaro A, Tang E, Zheng X. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy. 2023 Oct 13;72(12):3875–93.
Liu D, Yan J, Ma F, Wang J, Yan S, He W. Reinvigoration of cytotoxic T lymphocytes in microsatellite instability-high colon adenocarcinoma through lysosomal degradation of PD-L1. Nature Communications [Internet]. 2024 Aug 13 [cited 2024 Oct 13];15(1). Available from: https://pubmed.ncbi.nlm.nih.gov/39134545/
Adashek JJ, Kato S, Sicklick JK, Lippman SM, Razelle Kurzrock. If it’s a target, it’s a pan-cancer target: Tissue is not the issue. Cancer treatment reviews. 2024 Apr 1;125:102721–1.
Liu H, Chen X, Wang P, Chen M, Deng C, Qian X, et al. PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis. Cell Death and Disease [Internet]. 2024 Feb 24 [cited 2024 Oct 13];15(2). Available from: https://pubmed.ncbi.nlm.nih.gov/38402202/
Zhao L, Fu Y, Niu P, Zhang F, Jiao F, Zhou X, et al. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study. The Oncologist [Internet]. 2023 Apr 27 [cited 2024 Oct 13];28(10):e891–901. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546834/
Emiloju OE, Sinicrope FA. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer. JAMA Oncology [Internet]. 2023 Sep 7 [cited 2024 Oct 13];9(12):1708–8. Available from: https://pubmed.ncbi.nlm.nih.gov/37676680/
Fan WX, Su F, Zhang Y, Zhang XL, Du YY, Gao YJ, et al. Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer. Biomarker Research [Internet]. 2024 Aug 26 [cited 2024 Oct 13];12(1). Available from: https://pubmed.ncbi.nlm.nih.gov/39183366/
Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. European Journal of Cancer [Internet]. 2022 Nov 1;175:136–57. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0959804922004464
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maksymilian Janeczek, Julia Plewniok, Maria Partyka, Julia Wójcik, Karolina Kinga Kantor, Marcin Cholewa, Wiktoria Maria Szymańska, Karolina Jaglarz, Maciej Kuca, Kacper Wojciech Pamuła
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 94
Number of citations: 0
